- NASDAQ:INO sheds a further 2.95% on Friday as the stock continues to sink.
- Yet no sign that the FDA has loosened its stance on Inovio’s vaccine administrator: Cellectra 2000.
- Recent reports have indicated that although SARS-CoV-2 may be changing, existing vaccine candidates should still be effective.
NASDAQ:INO has continued to trend downwards as the stock dropped another 2.95% to close the week on Friday. From its high point on Tuesday, shares have plunged over 10% to its current price levels of $11.85 as Inovio approaches some of its lowest range of prices over the past six months. Shares have now dropped over 30% during the last month as investors grow weary of the future outlook of Inovio’s stalled COVID-19 vaccine candidate: INO-4800.
It is not only INO-4800 that the FDA had questions about, but the vaccine administrator as well. The Cellectra 2000 as it is named, issues a brief electrical pulse to open small skin pores where the vaccine enters and instructs cells to create the antigen. It remains unclear which part of the administrator the FDA had issues with. Shares have been beatdown ever since Inovio’s COVID-19 vaccine trials were paused and the longer that this goes on, it is likely that we will see the stock continue to struggle.
Inovio Pharmaceuticals stock
According to a report published by Australian scientists, the ongoing evolution of the COVID-19 virus, also known as SARS-CoV-2, should have little to no effect on existing vaccine candidates. The test the Australian scientists ran actually used INO-4800 on ferrets to test the vaccine candidate’s efficacy against two different strains of SARS-CoV-2. The results from both strains were that the ferrets had good responses to the vaccine in both cases. This can only be seen as good news for all of the horses in the Operation Warp Speed race that is currently underway, although Inovio continues to lag behind its rivals as time goes on.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD clings to daily gains above 1.0650
EUR/USD gained traction and turned positive on the day above 1.0650. The improvement seen in risk mood following the earlier flight to safety weighs on the US Dollar ahead of the weekend and helps the pair push higher.
GBP/USD recovers toward 1.2450 after UK Retail Sales data
GBP/USD reversed its direction and advanced to the 1.2450 area after touching a fresh multi-month low below 1.2400 in the Asian session. The positive shift seen in risk mood on easing fears over a deepening Iran-Israel conflict supports the pair.
Gold holds steady at around $2,380 following earlier spike
Gold stabilized near $2,380 after spiking above $2,400 with the immediate reaction to reports of Israel striking Iran. Meanwhile, the pullback seen in the US Treasury bond yields helps XAU/USD hold its ground.
Bitcoin Weekly Forecast: BTC post-halving rally could be partially priced in Premium
Bitcoin price shows no signs of directional bias while it holds above $60,000. The fourth BTC halving is partially priced in, according to Deutsche Bank’s research.
Week ahead – US GDP and BoJ decision on top of next week’s agenda
US GDP, core PCE and PMIs the next tests for the Dollar. Investors await BoJ for guidance about next rate hike. EU and UK PMIs, as well as Australian CPIs also on tap.